Cumulus Neuroscience

United Kingdom
Belfast, Northern Ireland, United Kingdom

Company profile

Cumulus Neuroscience company profile

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
4
Total equity funding
$13.1M
Last funding
Series Unknown / $4.8M / 2025-07-08
Last equity funding
Series Unknown / $4.8M
Investors
8
Lead investors
3
Founders
3
Articles
54

Founders and investors

Founders

Brian MurphyRonan CunninghamRuth McKernan

Lead investors

Dementia Discovery FundInnovate UKWhiterock Finance

Investors

ACF InvestorsDementia Discovery FundInnovate UKLifeArcWhiterock Finance